Diabetes Centre, Isala, Zwolle, The Netherlands.
Langerhans Medical Research Group, Zwolle, The Netherlands.
BMJ Open. 2017 Oct 25;7(10):e015870. doi: 10.1136/bmjopen-2017-015870.
To investigate sex differences in survival of primary care treated patients with type 2 diabetes (T2D) in the Netherlands.
Primary care.
A total of 1815 patients who participated in a prospective observational cohort study (Zwolle Outpatient Diabetes Project Integrating Available Care (ZODIAC)) were included of which 56% was female. Inclusion took place in 1998, 1999 and 2001. Vital status was assessed in 2013.
Relative survival of men and women with T2D. The relative survival rate was expressed as the ratio of observed survival of patients divided by the survival of the general population in the Netherlands with comparable age.
After 14 years, 888 (49%) patients had died. The relative survival rate was 0.88 (0.81-0.94) for men and 0.82 (0.76-0.87) for women with T2D after 14 years (p value for difference between sexes=0.169). In patients without a history of cardiovascular diseases (CVD), the relative survival was 0.99 (0.94-1.05) in men and 0.92 (0.87-0.97) in women (p value for difference between sexes=0.046).
The survival of men and women with T2D was 12% and 18% lower, respectively, after 14 years of follow-up compared with men and women in the general population. This corresponds to a decrease in median survival of 2.2 and 3.5 years in men and women, respectively. Only for patients with T2D without a history of CVD, a significantly lower relative survival in women compared with men with T2D was found.
研究荷兰初级保健治疗的 2 型糖尿病(T2D)患者的生存性别差异。
初级保健。
共纳入 1815 名参加前瞻性观察队列研究(Zwolle 门诊糖尿病项目整合可用护理(ZODIAC))的患者,其中 56%为女性。纳入时间为 1998 年、1999 年和 2001 年。2013 年评估了生存状况。
T2D 男性和女性的相对生存率。相对生存率表示患者观察生存率与荷兰具有可比年龄的普通人群生存率之比。
14 年后,888 名(49%)患者死亡。男性 T2D 患者 14 年后的相对生存率为 0.88(0.81-0.94),女性为 0.82(0.76-0.87)(性别间差异的 p 值=0.169)。在无心血管疾病(CVD)病史的患者中,男性的相对生存率为 0.99(0.94-1.05),女性为 0.92(0.87-0.97)(性别间差异的 p 值=0.046)。
与普通人群相比,男性和女性 T2D 患者在随访 14 年后的生存率分别降低了 12%和 18%。这相当于男性和女性的中位生存时间分别缩短了 2.2 年和 3.5 年。只有在没有 CVD 病史的 T2D 患者中,才发现女性的相对生存率明显低于男性 T2D 患者。